Efficacy and Safety of Condoliase Disc Administration as a New Treatment for Lumbar Disc Herniation
Masahiro Inoue, Takeshi Sainoh, Atsushi Kojima, Masatsune Yamagata, Tatsuo Morinaga, Chikato Mannoji, Hiromi Ataka, Masaomi Yamashita, Hiroshi Takahashi, Junya Saito, Takayuki Fujiyoshi, Tetsuhiro Ishikawa, Yawara Eguchi, Kei Kato, Sumihisa Orita, Kazuhide Inage, Yasuhiro Shiga, Masaki Norimoto, Tomotaka Umimura, Yuki Shiko, Yohei Kawasaki, Yasuchika Aoki, Seiji Ohtori
Abstract
INTRODUCTION: Condoliase is a newly approved drug that improves symptoms associated with lumbar disk herniation (LDH) by intradiscal administration. This study aimed to evaluate the mid-term outcomes of condoliase injection, examine the adverse events, including cases that required surgery after condoliase administration, and verify cases in which condoliase could be effective. METHODS: We enrolled patients with LDH who were treated conservatively for at least six weeks and received condoliase. We assessed the visual analog scale (VAS) score, Japanese Orthopaedic Association Back Pain Evaluation Questionnaire, Oswestry Disability Index, disk height, and disk degeneration for up to 6 months, and we examined the complications. Furthermore, a 50% or more improvement in leg pain VAS score was considered effective. Factors related to symptom improvement were investigated by determining whether lower limb pain improved in six months. RESULTS: = 0.029; odds ratio, 5.94; 95% confidence interval, 1.20-29.45) were significantly associated with clinical effectiveness. CONCLUSIONS: Condoliase disk administration improved pain and quality of life over time. Condoliase disk administration was more effective in L5/S1 intervertebral administration.